18/04/2026
Beyond Drops: The Shift Toward Interventional Glaucoma
For many years, glaucoma treatment has followed a familiar pattern — starting with eye drops and only escalating when the disease worsens.
In reality, this approach can be challenging. Many patients struggle with long-term use of drops, whether due to compliance, side effects, or simply the burden of daily treatment. Missed doses and follow-ups are common, and this can affect both outcomes and quality of life.
Glaucoma care is now moving toward a more proactive approach.
With options such as laser (SLT) and minimally invasive glaucoma surgery (MIGS), it is possible to intervene earlier — not just when progression occurs. These treatments play an important bridging role between medications and traditional surgery, with good safety profiles and quicker recovery.
At the same time, glaucoma management is becoming increasingly personalised, with treatment decisions guided by each patient’s lifestyle, treatment adherence and long-term visual needs.
The goal has not changed: to preserve vision for as long as possible.
But how we get there is evolving — with a greater focus on earlier intervention, reducing treatment burden and improving overall quality of life.
超越眼药水：迈向介入性青光眼治疗的转变
多年来，青光眼的治疗模式一直较为传统——从眼药水开始，只有在病情进展时才逐步升级治疗。
然而在实际临床中，这种方式也面临不少挑战。许多患者在长期使用眼药水时，会遇到依从性不足、副作用，以及日常用药带来的负担。漏用药物及复诊不规律的情况并不少见，进而影响治疗效果及整体生活质量。
随着治疗理念的演进，青光眼管理正逐渐转向更为主动的策略。
借助激光治疗（SLT）及微创青光眼手术（MIGS），我们有机会在疾病进展前更早进行干预。这些治疗方式在药物治疗与传统手术之间发挥着重要的桥梁作用，同时具备良好的安全性及更快的恢复速度。
与此同时，青光眼管理也日益趋向个体化。治疗决策不再仅依据疾病严重程度，还会综合考虑患者的生活方式、用药依从性以及长期视觉需求。
青光眼治疗的核心目标始终不变：尽可能延长并保护患者的视功能。
而实现这一目标的路径正在改变——更加重视早期治疗、减轻治疗负担，并提升整体生活质量。
Ever felt stuck in a glaucoma treatment rut? This eye-opening mini-documentary explores how leading specialists are completely rewriting the glaucoma treatme...
